Current Edition

Europe

Madrigal scores in mid-stage NASH study

Madrigal Pharmaceuticals on Thursday reported highly anticipated results for its Phase 2 non-alcoholic steatohepatitis (NASH) drug MGL-3196, unveiling positive data after 36 weeks. The study …

Continue Reading →